SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike (NKE) is trending lower after its latest earnings report, despite surpassing revenue and EPS estimates, driven by concerns over declining gross margins, weak direct-to-consumer sales, and ongoing softness in China. The community is sharply divided, with many debating if this presents a strong buying opportunity for the iconic brand or signals continued challenges amid intense competition and questions about product innovation and leadership.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is actively trending following news of its merger with TAE Technologies, positioning the company as an early publicly traded entrant in the fusion energy sector. This dramatic pivot from social media to "fusion + AI power" is driving intense community discussion and high volatility. While many anticipate significant upside and a short squeeze, others remain skeptical, viewing it as a speculative play with concerns over profitability and dilution.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending due to a recent analyst upgrade with a $20 price target and strong market anticipation for NASA's multi-billion dollar Lunar Terrain Vehicle (LTV) contract award. The community believes LUNR is a leading contender for this critical lunar mission, fueled by a renewed government focus on space exploration and broader investor enthusiasm for the sector, which many expect could trigger a significant short squeeze.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending amid discussions surrounding the Bank of Japan's monetary policy and its potential effects on the crypto market, especially Ethereum. A major community talking point involves a proposed share authorization, sparking intense debate between those fearing significant dilution and others seeing it as a strategic move to increase Ethereum holdings. This, coupled with recent market volatility and scrutiny over prominent analyst predictions, highlights significant uncertainty and strong opinions on BMNR's future as an Ethereum-linked asset.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber Inc. (WYFI) is trending following the announcement of a substantial 10-year, $865 million colocation agreement with Nscale for its NC-1 data center campus, securing 40 MW for AI infrastructure. The community views this as a significant catalyst, improving revenue visibility and fueling expectations for a potential multi-day rally and short squeeze given the company's low free float. This strategic deal reinforces WhiteFiber's role in the booming AI data center sector, which continues to see high demand for specialized capacity.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is a major topic of conversation as markets react to the Bank of Japan's interest rate decision, with community sentiment sharply divided on whether the move is already priced in or will trigger an unwind of the yen carry trade. This critical event, coupled with recent scrutinized inflation data and a significant options expiry, is fueling intense debate about broader market direction and volatility.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is trending as investors keenly evaluate its role as a short-term inflation-protected investment amidst persistent inflation concerns and broader market volatility. Community discussions center on its perceived value as a safe-haven asset for stable income, with many viewing it as potentially undervalued despite recent price movements, while also debating its effectiveness compared to other inflation hedges.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as the market reacts to the Bank of Japan's rate hike decision, sparking widespread debate among investors on its impact, particularly concerning the yen carry trade. This event, coupled with mixed community reactions to recent inflation data and ongoing concerns about an AI bubble, is driving high volatility and varied market predictions.

KB Home engages in selling and building a variety of new homes. It builds various types of homes, including attached and detached single-family homes, townhomes, and condominiums. The firm operates through the following segments: West Coast, Southwest, Central, and Southeast. It offer homes in development communities, at urban in-fill locations and as part of mixed-use projects. The company was founded in 1957 and is headquartered in Los Angeles, CA.

KB Home

KB Home is trending as investors weigh its recent earnings and forward guidance against a volatile housing market. Community discussion is split, with some anticipating a sector revival driven by potential interest rate moderation and "big money" interest, while others remain cautious due to ongoing affordability challenges and concerns about slowing demand. The company's performance and outlook are central to a broader debate on the homebuilding sector's resilience in the current economic climate.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is a focal point for investors following preliminary FLAMINGO-01 trial data, which reported an estimated 80% reduction in breast cancer recurrence rates from its open-label arm. This positive update, combined with an extremely high cost-to-borrow rate and a tightly held low float, is fueling intense short squeeze speculation and buyout discussions among the community. However, some investors are closely scrutinizing the preliminary nature of the data due to the absence of a direct placebo comparator.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESSA Announces Completion of Arrangement with XenoTherapeutics

ESSA Announces Completion of Arrangement with XenoTherapeutics ESSA Announces Completion of Arrangement with XenoTherapeutics PR Newswire SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada...

Shares of Essa Pharma, Inc. (<a class="mention" data-mention="$EPIX" data-symbol-id="EPIX" href="https://stocktwits.com/symbol/EPIX" target="_blank">$EPIX</a>) plummeted 70% on Friday morning after the company announced it would end its Phase 2 study of masofaniten, its lead drug candidate for prostate cancer.&nbsp;Essa’s decision follows an interim analysis indicating that the study was unlikely to meet its primary endpoint, a move aimed at prioritizing patient benefit and safety.&nbsp;CEO David Parkinson noted that the trial’s emerging efficacy profile for masofaniten, when combined with enzalutamide, was insufficient to justify continuation.Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review to explore options for maximizing shareholder value.&nbsp;JonesResearch analyst Soumit Roy downgraded Essa Pharma to ‘Hold’ from ‘Buy,’ saying “we were wrong in our assessment of masofaniten's potential.”&nbsp;Roy also anticipates the stock to trade at a 40%-50% discount to its cash per share, currently $2.64, until further guidance from management.<figure class="image"><a href="https://stocktwits.com/symbol/EPIX"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_01_at_9_42_09_AM_25b012ad7e.png" alt="Screenshot 2024-11-01 at 9.42.09 AM.png" width="1314" height="320"></a><figcaption>EPIX sentiment and message volume on Nov. 1 as of 9:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned ‘extremely bearish’ (9/100), the lowest in a year, with several users questioning the company’s pipeline viability.&nbsp;Some predicted a continued slide, with expectations of the stock trading below $1 as large shareholders exit their positions for tax write-offs.<stembedurl>https://stocktwits.com/StarLord13/message/590874905</stembedurl><stembedurl>https://stocktwits.com/elmono/message/590874567</stembedurl>Essa’s stock is down about 20% year-to-date as of Thursday’s close.&nbsp;Shares of the company are currently trading at their lowest level in over two years.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/wayfair-stock-rises-on-q3-earnings-beat/cJEYA3ARBk">Wayfair Thrills Retail Crowd As Stock Soars Premarket On Big Q3 Earnings Beat</a>

Shares of Essa Pharma are currently trading at their lowest level in over two years.

Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review

Equity

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review


ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Essa Pharma Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

EPIX
Essa Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EPIX News

EPIXEssa Pharma Inc